Nuvectis Pharma Investor Presentation Deck
NXP900 Key Highlights
Precision Medicine
Approach
Differentiated
Features
Strong Preclinical Proof
of Concept
Phase 1 Program
NuvectisPharma, Inc.
* Discovered at the University of Edinburgh, Scotland
* A potent, novel, small molecule inhibitor of YES1/SRC signaling
ā YES1-Hippo pathway alteration associated with sensitivity to NXP900 in squamous cell models
Highly selective
Unique mechanism of action - Complete shut-down of the SRC pathway by scaffold and
catalytic domain inactivation
POC in multiple xenograft models - significant single-agent activity in squamous cell cancer models
* Ability to re-sensitize resistant NSCLC cells to osimertinib
Ability to reverse resistance to enzalutamide in vivo in mCRPC
ā
Phase 1a dose escalation clinical trial ongoing
15View entire presentation